Using targeted therapies to improve treatment outcomes for malignant pleural mesothelioma
Targeting the Mitochondria to Overcome Resistance to Immune Checkpoint Inhibition in Malignant Pleural Mesothelioma
This study is looking at new ways to treat malignant pleural mesothelioma, a type of cancer caused by asbestos, by using special medicines that help your immune system fight the cancer better, and it’s for patients who don’t have many treatment choices right now.
Quick facts
| Grant type | R37 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Baylor College of Medicine NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project ID | NIH-11053605 on NIH RePORTER |
What this research studies
This research investigates new treatment strategies for malignant pleural mesothelioma (MPM), a cancer linked to asbestos exposure. The approach focuses on enhancing the effectiveness of immune checkpoint inhibitors (ICIs) by targeting mitochondrial functions in cancer cells. Patients will receive either ICIs or chemotherapy combined with ICIs, followed by surgical removal of the tumor. The goal is to improve survival rates and treatment responses in patients who currently have limited options.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with malignant pleural mesothelioma who are considering treatment options involving immune checkpoint inhibitors.
Not a fit: Patients with advanced-stage mesothelioma who are not candidates for surgery or those with other severe comorbidities may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could significantly improve survival rates and quality of life for patients with malignant pleural mesothelioma.
How similar studies have performed: Previous studies have shown promising results with immune checkpoint inhibitors in treating malignant pleural mesothelioma, indicating potential for success with this novel approach.
Where this research is happening
Houston, United States
- Baylor College of Medicine — Houston, United States (Active)
Researchers
- Principal investigator: Ripley, Robert Taylor — Baylor College of Medicine
- Study coordinator: Ripley, Robert Taylor
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.